Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04792502 · ClinicalTrials.gov registry record · Phase 2
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
A Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by Brown University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 3
- Study locations
NCT04792502: Recruiting Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by Brown University.
NCT04792502 is a Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma that is actively recruiting participants, run by Brown University. The registered enrollment target is 52 participants, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (61% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04792502, a Phase 2 study of Follicular Lymphoma and Marginal Zone Lymphoma, is actively recruiting participants, sponsored by Brown University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 3
- Study locations
Study Summary
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 21-day cycles (C1-4) of mosunetuzumab alone (using step-up dosing during C1), followed by IRA. Patients who achieve CR at IRA will continue with additional 4 cycles (C5-8) of mosunetuzumab. Patients who achieve PR at IRA will receive mosunetuzumab with lenalidomide augmentation during C5-8. Primary response assessment (PRA) will occur after C8. Patients who remain in PR at PRA will continue for additional 4 cycles (extended augmentation).
Primary Outcome
The rate of complete response at the time of primary response assessment (PRA).
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG Lenalidomide
Study Locations (3)
Connecticut
- Yale Cancer Center - New Haven
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Rhode Island
- Lifespan Cancer Insitute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
What NCT04792502 shows while recruiting
NCT04792502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (61% lower).
The record links to 3 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Mosunetuzumab is the first listed.
NCT04792502 reports a single indexed study location in Connecticut, New Jersey, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT04792502 about?
NCT04792502 is a clinical study titled "Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma". BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 2...
What is the current status of trial NCT04792502?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2022-07-14. Estimated completion is 2027-08-31.
What conditions does trial NCT04792502 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma.
What interventions are being tested in trial NCT04792502?
The interventions under investigation include: Mosunetuzumab (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT04792502?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04792502 being conducted?
This trial has 3 study locations across Connecticut, New Jersey, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04792502's enrollment target sits among peer trials
52 43rd of 89 higher than 47 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI